CARPHA CRS Recommends its First Biosimilar Product to help with Cancer Management
The CARPHA Caribbean Regulatory System (CRS) recently recommended its first biosimilar product which can become part of the support to cancer management in its Member States. Pegfilgrastim, the active ingredient, is designed to boost the body’s immune response, thereby allowing cancer patients to keep fighting infections while receiving cancer treatments, such as chemotherapy, that harm blood cell production. It may be used in the management of various cancers.
For more information go to http://new.carpha.org/What-We-Do/Programmes-and-Projects/CRS/Caribbean-Regulatory-System